SCHEMBL6404920

SCHEMBL6404920

CC(C)C(O)CS(=O)(=O)Cc1cnc2ccccc2c1.CC(C)C=CS(=O)(=O)Cc1cnc2ccccc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
MMP9 P14780 2/20 0.36
MMP1 P03956 1/20 0.36
FCER2 P06734 1/20 0.36
MMP3 P08254 1/20 0.36
CYP1A2 P05177 1/20 0.35
HIF1A Q16665 1/20 0.35
EPAS1 Q99814 1/20 0.35
PDE10A Q9Y233 5/20 0.34
MMP2 P08253 2/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TRPM5 Q9NZQ8 1/20 0.33
PTGES O14684 1/20 0.33
ALOX5 P09917 1/20 0.33
ACACB O00763 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6606473 0.89 CYP1A2 (0.42) KMT2AMMP9MMP1FCER2MMP3
SCHEMBL6398979 0.88 CYP1A2 (0.43) KMT2AMEN1MMP9CYP1A2HIF1A
SCHEMBL6398986 0.88 CYP1A2 (0.43) KMT2AMEN1MMP9CYP1A2HIF1A
SCHEMBL6986645 0.79 CYP1A2 (0.43) KMT2AMMP9MMP1FCER2MMP3
SCHEMBL6404912 0.76 CYP1A2 (0.34) KMT2AMEN1MMP9MMP1FCER2
SCHEMBL6606289 0.75 CYP1A2 (0.42) KMT2AMMP9MMP1FCER2MMP3
SCHEMBL6399016 0.74 MMP2 (0.40) KMT2AMMP9MMP1FCER2MMP3
SCHEMBL6399014 0.74 MMP2 (0.40) KMT2AMMP9MMP1FCER2MMP3
SCHEMBL6987795 0.74 CYP1A2 (0.43) KMT2AMMP9MMP1FCER2MMP3
SCHEMBL6981602 0.73 CYP1A2 (0.38) KMT2ACYP1A2HIF1AEPAS1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US disclosed
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 KMT2A 2661/4885MEN1 2010/4885MMP9 3613/4885
US-20040024066-A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides CD22, CD2, NEU3 KMT2A 2906/4885MEN1 1518/4885MMP9 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.